Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age
Conditions
Interventions
Meningococcal vaccine GSK134612
Cervarix®
+1 more
Locations
3
Dominican Republic
GSK Investigational Site
Santo Domingo, Dominican Republic
GSK Investigational Site
Tartu, Estonia
GSK Investigational Site
Bangkok, Thailand
Start Date
January 11, 2013
Primary Completion Date
April 29, 2014
Completion Date
April 29, 2014
Last Updated
July 3, 2018
NCT04886154
NCT01962207
NCT00508261
NCT00974363
NCT00126984
NCT00196963
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions